Ernexa Therapeutics (ERNA) vs GRI Bio (GRI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
GRI Bio is the larger company by market cap ($2.4 million vs $2.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERNA | GRI |
|---|---|---|
| Share price | $1.36 | $1.12 |
| Market cap | $2.30M | $2.45M |
| 1-day change | -16.56% | 0.00% |
| P/E ratio (TTM) | — | 0.05 |
| EPS (TTM) | $-11.22 | $20.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-14.08M | $-11.96M |
| 52-week high | $37.50 | $64.12 |
| 52-week low | $1.35 | $1.09 |
| Distance from 52-week high | -96.37% | -98.25% |
| Analyst consensus | none | none |
| Avg. price target upside | +2105.88% | +1551.79% |
| Average volume | 43.90K | 218.31K |
| Shares outstanding | 1.69M | 2.19M |
| Employees | 5 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ernexa Therapeutics
ERNA stock →Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About GRI Bio
GRI stock →GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
ERNA vs GRI FAQ
Which is bigger, Ernexa Therapeutics or GRI Bio?
GRI Bio (GRI) is larger, with a market capitalization of $2.45M compared with $2.30M for Ernexa Therapeutics (ERNA).
Are Ernexa Therapeutics and GRI Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.